<DOC>
	<DOCNO>NCT00788164</DOCNO>
	<brief_summary>RATIONALE : Vaccines make DNA gene-modified virus may help body build effective immune response kill tumor cell . Biological therapy , imiquimod , may stimulate immune system different way stop tumor cell grow . Applying topical imiquimod cervix may effective treatment cervical intraepithelial neoplasia . Giving vaccine therapy together imiquimod may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy see well work give without imiquimod treat patient grade 3 cervical intraepithelial neoplasia .</brief_summary>
	<brief_title>Vaccine Therapy With Without Imiquimod Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate safety , tolerability , feasibility pNGVL4a-Sig/E7 ( detox ) /HSP70 DNA vaccine TA-HPV vaccine without imiquimod patient human papillomavirus ( HPV ) 16-positive grade 3 cervical intraepithelial neoplasia ( CIN3 ) . Secondary - To evaluate effect regimen histology , base regression cervical intraepithelial neoplasia . - To evaluate feasibility safety study immunotherapy patient . - To evaluate quantitative change cervical HPV viral load patient follow study immunotherapy . - To evaluate change lesion size . - To evaluate cellular humoral immune response vaccination . - To evaluate local tissue immune response . - To correlate measure immune response clinical response . - To correlate measure immune response observe preclinical model . - To evaluate efficacy prime-boost vaccination improve cervical application imiquimod . OUTLINE : This dose escalation study TA-HPV vaccine ( group 1-3 ) . Patients assign 1 5 treatment group . - Groups 1-3 : Patients receive pNGVL4a-Sig/E7 ( detox ) /HSP70 DNA vaccine intramuscularly ( IM ) week 0 4 TA-HPV vaccine IM week 8 . - Group 4 : Patients receive topical imiquimod apply cervix week 0 , 4 , 8 . - Group 5 : Patients receive pNGVL4a-Sig/E7 ( detox ) /HSP70 DNA vaccine TA-HPV vaccine group 1-3 , imiquimod group 4 . Patients experience improvement lesion week 15 undergo standard cone resection squamocolumnar junction . If either 1 ) regression size lesion colposcopy and/or 2 ) CIN3 lesion detect colposcopy/biopsy Pap smear and/or 3 ) significant decrease HPV viral load , patient follow week 28 . At time , loop electrosurgical excision procedure ( LEEP ) resection perform CIN3 lesion detect colposcopy/biopsy suspect Pap smear . Patients undergo LEEP follow week 32 . Patients undergo LEEP follow week 41 confirm CIN3 regression . Blood tissue sample collect periodically measure immune response via ELISA , determine viral load identify co-infecting HPV type via reverse-line blotting , analyze lymphocytes via flow cytometry . PROJECTED ACCRUAL : A total 36 patient ( 3 group 1 2 , 12 group 3 5 , 6 group 4 ) accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Colposcopically biopsy confirm grade 3 cervical intraepithelial neoplasia Human papillomavirus ( HPV ) 16positive disease PCR Measurable disease diagnostic biopsy No concurrent adenocarcinoma situ cervix PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective form contraception study treatment Immunocompetent No concurrent malignancy , except nonmelanoma skin lesion No serious concurrent disorder , include follow : Active systemic infection Autoimmune disease Proven suspect immunosuppressive disorder Major medical illness cardiovascular respiratory system No evidence history cardiac disease , include follow : Congestive heart failure Symptomatic arrhythmia control medication Unstable angina History acute myocardial infarction cerebrovascular accident within past 6 month No history severe allergy include eczema exfoliative skin disorder No active eczema within past 12 month No concurrent skin condition , include follow : Burns Traumatic pruritic skin condition Open wound Unhealed surgical scar Patients close social , sexual , domestic contact may follow active skin disease : Psoriasis Lichen planus Sever acneiform rash Impetigo Varicella zoster Sepsis No close social contact child 5 year old No close social domestic contact pregnant woman No HIV seropositivity No allergy egg PRIOR CONCURRENT THERAPY : No previous vaccination vaccinia No immunosuppressive medication ( i.e. , steroid therapy immunosuppressive/immunomodulating drug [ e.g. , cyclosporine ] ) within past 2 month No investigational agent ( ) within past 6 month No concurrent participation another experimental protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia grade 3</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>treatment</keyword>
	<keyword>CIN</keyword>
	<keyword>HPV</keyword>
	<keyword>vaccine</keyword>
	<keyword>Hopkins</keyword>
	<keyword>Trimble</keyword>
</DOC>